首页> 外文期刊>Biotechnology Progress >A TGF‐α and TGF‐β1 Poloxamer‐based micelle/hydrogel composite: A promising novel candidate for the treatment of anosmia
【24h】

A TGF‐α and TGF‐β1 Poloxamer‐based micelle/hydrogel composite: A promising novel candidate for the treatment of anosmia

机译:A TGF‐α and TGF‐β1 Poloxamer‐based micelle/hydrogel composite: A promising novel candidate for the treatment of anosmia

获取原文
获取原文并翻译 | 示例
       

摘要

Abstract Anosmia is the inability to smell or loss of the sense of smell. It can reduce your ability to detect the smell of smoke, gas leaks, or spoiled food, as well as hinder the quality of life related to social interactions and feelings of well‐being. In the current study, a drug delivery composite was designed to cure anosmia and its efficiency in delivering transforming growth factor alpha (TGF‐α) and transforming growth factor beta 1 (TGF‐β1) to the nasal cavity was evaluated. Bovine serum albumin (BSA) was used as a model protein for encapsulation into Poloxamers 407 micelles. For the optimization of the BSA‐micelle formulation, a two‐parameter five‐level central composite design (CCD) was applied. The BSA‐micelle was optimized with a particle size of 41 nm, drug loading of 8%, and encapsulation efficiency of 74%. Further, the BSA‐micelle was characterized by FESEM, TEM, and FTIR. The analysis of release profile suggested high‐paced free BSA release compared to the gradual and prolonged release of BSA‐micelle/hydrogel and BSA‐micelles. The cytotoxicity assay demonstrated the safety of TGF‐α and TGF‐β1‐micelles/hydrogel. Moreover, it was observed that TGF‐α and TGF‐β1 within the hydrogels promote cellular viability and human olfactory ectomesenchymal stem cell OE‐MSCs proliferation. In conclusion, According to the results of our study, the TGF‐α and TGF‐β1‐micelle/hydrogel‐based delivery system provides a suitable alternative for anosmia treatment.

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号